Article Text

Download PDFPDF
Using targeted therapies at the end of life
  1. Matthieu Delaye1,
  2. Florian Scotte2,
  3. Sabine Voisin-Saltiel1,
  4. Elena Pavliuc1,
  5. Laurence Vigouret-Viant1,
  6. Sarah Dauchy2 and
  7. Christine Mateus1
  1. 1 Palliative Care Unit, Gustave Roussy Institute, Villejuif, France
  2. 2 Department of Supportive Care, Gustave Roussy Institute, Villejuif, France
  1. Correspondence to Matthieu Delaye, Gustave Roussy Institute, Villejuif, France; matthieu.delaye{at}


The prescription of chemotherapy during the last weeks of a patient’s life is a recognised criterion of decreasing quality of life but also survival. Targeted therapies have a particular efficiency and tolerance profile raising the question of their use in a palliative setting. Two patients were treated for a melanoma, at terminal stage, with poor efficiency of the symptomatic treatments. We introduced targeted therapies, which was previous treatments used in both patients.The evolution and benefits of the treatment was very different in our two patients and make us discuss the interest of targeted therapies in an end-of-life context and propose criteria for their maintenance or introduction in this indication. This discussion requires close collaboration between oncologists and palliative physicians and a very clear information given to patients and their relatives.

  • supportive care
  • end of life care
  • quality of life
  • symptoms and symptom management

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors MD: data curation, writing—original draft preparation. SV-S, EP and LV-V: supervision. CM and FS: visualisation, writing—reviewing and editing.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.